Leadership at the Centers for Medicare and Medicaid Services is working with states to develop plans to use the $50 billion ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach ...

Dr. Mehmet Oz, administrator for the Centers for Medicare & Medicaid Services, discusses the Trump administration’s efforts ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

In an exclusive interview with Yahoo Finance's Decoding Retirement podcast, Mehmet Oz, the administrator of the Centers for ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

The government can't combat this problem alone. Seniors can do a lot to protect themselves and the system. And we should all be alert for scams.

The latest public gaffe came as the Trump administration is encouraging millions of Americans to transfer their personal ...

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so.

Trump is changing Medicare, mostly focusing on providers. But the biggest impact may come from tariffs and deporting ...